Research ArticleBasic Science Investigations
Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
Matthias Glaser, Peter Iveson, Susan Hoppmann, Bård Indrevoll, Anthony Wilson, Joseph Arukwe, Antonios Danikas, Rajiv Bhalla and Duncan Hiscock
Journal of Nuclear Medicine November 2013, 54 (11) 1981-1988; DOI: https://doi.org/10.2967/jnumed.113.122465
Matthias Glaser
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and
Peter Iveson
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and
Susan Hoppmann
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and
Bård Indrevoll
2GE Healthcare, Oslo, Norway
Anthony Wilson
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and
Joseph Arukwe
2GE Healthcare, Oslo, Norway
Antonios Danikas
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and
Rajiv Bhalla
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and
Duncan Hiscock
1GE Healthcare, Amersham, Buckinghamshire, United Kingdom; and

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 54, Issue 11
November 1, 2013
Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
Matthias Glaser, Peter Iveson, Susan Hoppmann, Bård Indrevoll, Anthony Wilson, Joseph Arukwe, Antonios Danikas, Rajiv Bhalla, Duncan Hiscock
Journal of Nuclear Medicine Nov 2013, 54 (11) 1981-1988; DOI: 10.2967/jnumed.113.122465
Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
Matthias Glaser, Peter Iveson, Susan Hoppmann, Bård Indrevoll, Anthony Wilson, Joseph Arukwe, Antonios Danikas, Rajiv Bhalla, Duncan Hiscock
Journal of Nuclear Medicine Nov 2013, 54 (11) 1981-1988; DOI: 10.2967/jnumed.113.122465
Jump to section
Related Articles
Cited By...
- Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
- 18F-AlF-Labeled Biomolecule Conjugates as Imaging Pharmaceuticals
- In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
- Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET
- Reply: Al18F Labeling of Affibody Molecules
- Al18F Labeling of Affibody Molecules
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies